Searchable abstracts of presentations at key conferences in endocrinology

ea0014p139 | (1) | ECE2007

Survivin – a promising target for immunotherapy in patients with adrenocortical carcinoma

Fassnacht Martin , Wortmann Sebastian , Sbiera Silviu , Kuehner Dorothee , Wobser Marion , Adam Patrick , Becker Juergen C. , Allolio Bruno

Objectives: Adrenocortical carcinoma (ACC) is a rare tumor with poor prognosis and limited therapeutic options. Survivin is an anti-apoptotic molecule expressed by neoplastic and tumor-specific endothelial cells of various carcinomas, but rarely or only weakly in normal differentiated tissue. In melanoma and pancreatic cancer, preliminary results of a survivin vaccination trial ( indicated that an immunological response in patients is often paralleled by...

ea0020p182 | Endocrine tumours and neoplasia | ECE2009

Endocrine gland-derived vascular endothelial growth factor and its receptors in adrenocortical carcinoma

Sbiera Silviu , Kuehner Dorothee , Wortmann Sebastian , Adam Patrick , Voelker Hans-Ullrich , Kraus Luitgard , Beyer Melanie , Quinkler Markus , Willenberg Holger , Weismann Dirk , Hahner Stefanie , Allolio Bruno , Fassnacht Martin

Objectives: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF; also termed prokineticin-1) has been identified as a mitogen preferable for the endothelium of steroidogenic glands (1). EG-VEGF and its receptors (prokineticin receptors 1 and 2; PKR1 and 2) are highly expressed in the normal adrenal gland and an autocrine mitogenic loop has been proposed (2). Therefore, we investigated the expression of EG-VEGF and its receptors in adrenocortical carcinoma (ACC)...